News

RXi is a clinical-stage RNAi firm focused on the development of new therapeutics to solve significant unmet medical needs. As per the deal terms, RXi would issue stock

The aim of the study was to determine the safety and clinical benefit fexapotide can provide to men who were given a second injection of fexapotide for their

The trial showed SUTENT extended disease-free survival (DFS) by more than one year versus placebo in patients who were at high risk for recurrence after surgical resection of

Following the strategic partnership entered between the two companies in 2014 to combine resources and scientific expertise within dermatology development, the parties have now agreed to fully leverage

The sBLA is based on results from the Phase III RADIANCE study that demonstrated treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to

Under the collaboration deal, Transgene will sponsor a phase 1/2 study to assess its therapeutic vaccine candidate TG4001 together with Merck and Pfizer's immunotherapy avelumab to treat human

Under the collaboration, Takeda will provide EnGeneIC with an upfront access fee and research funding to explore the feasibility of the EDV technology for the development of immunomodulatory

Aprea Therapeutics AB president and CEO Christian Schade said: "The initiation of the Phase II clinical study marks an important milestone for Aprea. "We are committed to developing and

SCIB2 will be studied in combination with a checkpoint inhibitor and follow the publication of data in journal OncoImmunology, which showed the drug demonstrated potent anti-tumour immunity. Data